Bicara Therapeutics (NASDAQ:BCAX) CEO Sells $400,750.00 in Stock

Bicara Therapeutics Inc. (NASDAQ:BCAX) CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction dated Tuesday, September 8th. The stock was sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the sale, the chief executive officer directly owned 181,641 shares in the company, valued at approximately $4,159,578.90. The trade was a 8.79% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Ryan Cohlhepp also recently made the following trade(s):

• On Monday, August 10th, Ryan Cohlhepp sold 18,750 shares of Bicara Therapeutics stock. The shares were sold at an average price of $27.98, for a total transaction of $524,625.00.
• On Thursday, July 9th, Ryan Cohlhepp sold 536 shares of Bicara Therapeutics stock. The shares were sold at an average price of $29.00, for a total transaction of $15,544.00.
• On Wednesday, July 8th, Ryan Cohlhepp sold 28,214 shares of Bicara Therapeutics stock. The shares were sold at an average price of $28.98, for a total transaction of $817,641.72.

Bicara Therapeutics Stock Performance

Bicara Therapeutics stock traded down $0.54 during midday trading on Thursday, reaching $23.10. 636,805 shares of the stock were exchanged, compared to its average volume of 596,594. The company’s fifty day moving average is $26.13 and its 200-day moving average is $22.92. The firm has a market cap of $1.53 billion, a PE ratio of -7.45 and a beta of -0.82. Bicara Therapeutics Inc. has a 52 week low of $10.30 and a 52 week high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX) last announced its quarterly earnings results on Tuesday, August 11th. The company reported ($0.82) EPS for the quarter, meeting the consensus estimate of ($0.82). On average, sell-side analysts anticipate that Bicara Therapeutics Inc. will post -3.51 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the company. Wells Fargo & Company increased their price objective on Bicara Therapeutics from $16.00 to $23.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 12th. Morgan Stanley boosted their target price on Bicara Therapeutics from $37.00 to $39.00 and gave the stock an “overweight” rating in a research report on Tuesday, August 11th. BTIG Research upped their target price on Bicara Therapeutics from $28.00 to $39.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Bicara Therapeutics in a report on Monday, July 6th. Finally, Wall Street Zen upgraded Bicara Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Sunday, May 24th. Two analysts have rated the stock with a Strong Buy rating, nine have assigned a Buy rating, three have given a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $32.64.

Hedge Funds Weigh In On Bicara Therapeutics

A number of institutional investors have recently made changes to their positions in the stock. Jupiter Topco LLC bought a new stake in Bicara Therapeutics during the second quarter worth about $93,957,000. Dimensional Fund Advisors LP increased its position in shares of Bicara Therapeutics by 166.9% during the 1st quarter. Dimensional Fund Advisors LP now owns 109,261 shares of the company’s stock valued at $2,170,000 after purchasing an additional 68,327 shares during the last quarter. Walleye Capital LLC bought a new position in shares of Bicara Therapeutics during the 2nd quarter valued at about $10,487,000. UBS Group AG raised its holdings in shares of Bicara Therapeutics by 97.4% during the 4th quarter. UBS Group AG now owns 192,191 shares of the company’s stock valued at $3,235,000 after buying an additional 94,829 shares in the last quarter. Finally, Candriam S.C.A. purchased a new position in shares of Bicara Therapeutics during the 1st quarter valued at about $4,750,000.

About Bicara Therapeutics

Bicara Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel neurohormone-based therapies for psychiatric and neurological disorders. The company’s research focuses on harnessing endogenous signaling pathways in the brain, with the goal of offering new treatment options for conditions that remain inadequately addressed by existing medications. Bicara applies proprietary peptide engineering and intranasal delivery platforms to optimize central nervous system uptake and therapeutic effect.

The company’s lead candidates include PST-001, an intranasal vasopressin-1A receptor antagonist in development for postpartum depression, and PST-002, an oxytocin receptor modulator being investigated for social anxiety and autism spectrum disorder.